about
DNA and the chromosome - varied targets for chemotherapyErbB2 degradation mediated by the co-chaperone protein CHIPTransthiocarbamoylation of proteins by thiolated isothiocyanates.Total synthesis of the Hsp90 inhibitor geldanamycin.Concentration-dependent processivity of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetase.The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derruboneNew potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation.Withaferin A targets heat shock protein 90 in pancreatic cancer cells.Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.Prion diseases: from molecular biology to intervention strategies.Synthesis of (6R)- and (6S)-5,10-dideazatetrahydrofolate oligo-gamma-glutamates: kinetics of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetaseNegative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.Regulation and function of nuclear IκBα in inflammation and cancerNatural product inhibitors of Hsp90: potential leads for drug discoveryNovobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitorReactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature.
P2860
Q24792540-A7CE262F-E29E-40DE-9DBB-D9B9335EEF1DQ28208008-71D92433-FED8-4B97-A8A0-3C3A6AD26690Q31035960-1B5611F4-3D79-485E-A0E5-D4C4DC3EEF52Q33335863-0019286B-9E62-4F9B-BAEF-5BB469956082Q33586350-FFDCEF33-973B-4D59-97EF-5A8E6D32EEBFQ33637496-90B9DD09-05DD-40AC-BF18-A9C4817EAAEFQ33920494-F00304A4-753B-4D6F-9ADE-7AA14E600D9FQ34542601-982CABC9-95F0-42C6-B1E1-D99D28026316Q35004306-C5A26279-336C-459A-A411-EDD251A65915Q35166852-E53BEBB0-34D5-43B2-B3A2-E9ED898F775FQ35602374-95E7F0AB-8ECA-43C7-955A-1DF0A4C69FD2Q36008563-289B00D4-642B-41D9-86DB-1AD87A8174E1Q36347988-39CFB44D-9AB2-45F0-B076-AC151F388A82Q37021647-C757D70A-A1C8-40CB-9FA4-E7CADCB2775CQ37136710-935CE72C-C59F-4198-B981-9B7A099F02D1Q37320252-3D917AA3-EC85-4E41-817F-2F106D133BAFQ41873320-B716707A-1D7E-41CE-B825-CC398D0CEBB6Q44488098-819FC24D-F74F-4613-995E-BEEE5E1C55ADQ47770721-5E610417-3F2A-4B3A-9DE2-54CBE05B9415
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
New agents in cancer clinical trials.
@ast
New agents in cancer clinical trials.
@en
New agents in cancer clinical trials.
@nl
type
label
New agents in cancer clinical trials.
@ast
New agents in cancer clinical trials.
@en
New agents in cancer clinical trials.
@nl
prefLabel
New agents in cancer clinical trials.
@ast
New agents in cancer clinical trials.
@en
New agents in cancer clinical trials.
@nl
P2860
P356
P1433
P1476
New agents in cancer clinical trials.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1204088
P407
P577
2000-12-01T00:00:00Z
P5875
P6179
1035135661